Abstract

The definition and management of ST-segment elevation myocardial infarction (STEMI) has changed considerably over the past few years. This article has been written as an update to encompass the National Service Framework (NSF) for coronary heart disease (published in England in March 2000 1 and in Wales in July 20012), the Scottish Intercollegiate Guidelines Network 3 and the recent Task Force Report by the European Society of Cardiology (January 2003).4
[download-attachments container="div" style="list" display_icon="1" display_count="1" display__size="0"]

References

1. National Service Framework for coronary heart disease. 2000, Department of Health.
2. Tackling Coronary Heart Disease in Wales: Implementing through Evidence. 2001, Department of Health for Wales.
3. Secondary prevention of coronary heart disease following myocardial infarction. 2000, Scottish Intercollegiate Guidelines Network.
4. Van de Werf, F., et al, Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J, 2003; 24(1): 28-66.
5. Eagle, K., Lessons from GRACE: the Global Registry of Acute Coronary Events. Eur Heart Journal, 2002. 4(Suppl. E): E24-E31.
6. Gersh, B.J., Acute myocardial infarction. Results of the ASSENT-3 Trial. Rev Cardiovasc Med, 2002. 3(2): 111-5.
7. Topol, E.J., Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet, 2001. 357(9272): 1905-14.
8. Tunstall-Pedoe, H., et al, Contribution of trends in survival and coronaryevent rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet, 1999; 353(9164): 1547-57.
9. Norris, R.M., Fatality outside hospital from acute coronary events in three British health districts, 1994-5. United Kingdom Heart Attack Study Collaborative Group. Bmj, 1998. 316(7137): 1065-70.
10. Kuch, B., et al, What is the real hospital mortality from acute myocardial infarction? Epidemiological vs clinical view. Eur Heart J, 2002. 23(9): 714-720.
11. Ryan, T.J., et al, 1999 update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation, 1999. 100(9): 1016-30.
12. Wong, C.K. and H.D. White, Recognising "painless" heart attacks. Heart, 2002; 87(1): 3-5.
13. White, H., Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet, 2001; 358(9296): 1855-63.
14. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet, 1994. 343(8893): 311-22.
15. Connolly, D.L., G.Y. Lip, and B.S. Chin, Antithrombotic strategies in acute coronary syndromes and percutaneous coronary interventions. Bmj, 2002; 325(7377): 1404-7.
16. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet, 1988; 2(8607): 349-60.
17. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet, 1996; 348(9038): 1329-39.
18. White, H.D., Thrombolytic therapy in the elderly. Lancet, 2000. 356(9247): 2028-30.
19. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med, 1993; 329(10): 673-82.
20. Maggioni, A.P., et al, The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico II (GISSI-2), and The International Study Group. N Engl J Med, 1992; 327(1): 1-6.
21. A comparison of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. N Engl J Med, 1997; 337(16): 1118-23.
22. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators. Lancet, 1999; 354(9180): 716-22.
23. Antman, E.M., et al, Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation, 1999; 99(21): 2720-32.
24. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Circulation, 2000; 101(24): 2788-94.
25. Ross, A.M., et al, Randomized comparison of enoxaparin, a lowmolecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation, 2001; 104(6): 648-52.
26. Wallentin, L., The ASSENT-3 PLUS trial. Presented at the 75th Scientific Sessions of the American Jeart Association, Chicago, 2002.
27. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. N Engl J Med, 1997; 336(23): 1621-8.
28. Weaver, W.D., et al, Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. Jama, 1997; 278(23): 2093-8.
29. Stone, G.W., et al, Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med, 2002; 346(13): 957-66.
30. Moon, J.C., P.R. Kalra, and A.J. Coats, DANAMI-2: is primary angioplasty superior to thrombolysis in acute MI when the patient has to be transferred to an invasive centre? Int J Cardiol, 2002; 85(2-3): 199-201.
31. NICE, Prophylaxis for patients who have experienced a myocardial infarction. 2001, National Institute for Clinical Excellence (NICE).
32. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet, 1994; 343(8906): 1115-22.
33. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet, 1995; 345(8951): 669-85.
34. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised double-blind, placebo-controlled, multicentre trial (the EUROPA study). The Lancet, 2003; 362(9386): 782-788.
35. Roberts, R., et al, Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation, 1991; 83(2): 422-37.
36. Pfisterer, M., et al, Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries. J Am Coll Cardiol, 1998; 32(3): 634-40.
37. Madsen, J.K., et al, Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI). DANish trial in Acute Myocardial Infarction. Circulation, 1997; 96(3): 748-55.
38. Lee, K.S., et al, Prognosis of patients with left ventricular dysfunction, with and without viable myocardium after myocardial infarction. Relative efficacy of medical therapy and revascularization. Circulation, 1994; 90(6): 2687-94.
39. De Lorgeril, M., Salen, P, Martin, J-L, et al, Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction. Final report of the Lyon Diet Heart Study. Circulation, 1999; 99: 779-785.
40. Freemantle, N., et al, beta Blockade after myocardial infarction: systematic review and meta regression analysis. Bmj, 1999; 318(7200): 1730-7.
41. Yusuf, S., et al, Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med, 2000; 342(3): 145-53.
42. Fath-Ordoubadi, F., Beatt. K.J, Glucose-insulin-potassium therapy of acute myocardial infarction: an overview of randomised controlled trials. Circulation, 1997; 96: 1152-6.
43. NICE, Management of type 2 diabetes. 2002, National Institute for Clinical Excellence (NICE).
44. Malmberg, K., Prospective randomized study of intensive insulin treatment on long-term survival after acute myocardial infaction in patient with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infacrction) Study Group. Bmj, 1997; 26: 57-65.